1. Professional audience
This website presents peptide API information for qualified business and institutional discussions. APIs are not finished medicines, and the website does not provide medical advice, diagnosis, treatment, dosage, administration, or patient guidance.
2. Product portfolio
The current public portfolio covers Semaglutide, Tirzepatide, and Retatrutide. Retatrutide remains investigational and is not approved for public use.
Molecular identity, supplied form, specification, target market, documentation, quantity, availability, timing, and commercial terms are confirmed for the applicable project and written offer.
3. Photography and technical graphics
Photography on this website presents LUMIRABIO facilities, equipment, laboratories, warehouses, and business activities. Molecular structures, charts, and technical graphics support product and process explanation.
4. Specifications and records
Public specifications describe the portfolio standard. The applicable specification, approved method, sample identity, batch result, issuer, and Certificate of Analysis govern the material proposed for an order.
Access to controlled documents is coordinated with the qualified organization and the relevant product, site, batch, and project scope.
5. Contact
For a product, documentation, or supply discussion, use the technical inquiry form or contact lumirabio@gmail.com.